ASX:TLXBiotechs
Is Telix (ASX:TLX) Using TLX101-Px To Quietly Reframe Its Brain Oncology Positioning?
On 17 February 2026, Telix Pharmaceuticals announced it had submitted a European marketing authorization application for TLX101-Px, an 18F-FET PET imaging agent for glioma, targeting major markets and aligning elements with a forthcoming U.S. FDA filing.
This move seeks to transform a physician-supervised, hospital-only imaging setup into a commercially distributed product, potentially broadening access to advanced brain cancer imaging and supporting Telix's glioblastoma therapy...